CD93 Double Nickase Plasmid (h): sc-407484-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD93 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD93 Double Nickase Plasmid (h) and CD93 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD93. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD93 Antibody (B-1): sc-365172
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD93 Double Nickase Plasmid (h) | sc-407484-NIC | 20 µg | $410.00 | |||
CD93 Double Nickase Plasmid (h2) | sc-407484-NIC-2 | 20 µg | $410.00 |
CD93 is a type I transmembrane glycoprotein expressed prominently on endothelial cells and cells of the myeloid lineage, where it participates in adhesion-associated signaling and regulation of inflammatory responses. It interfaces with extracellular matrix and complement-related processes to modulate leukocyte trafficking, efferocytosis, and vascular homeostasis, linking innate immune activity with tissue remodeling. CD93 activity is commonly studied in the context of angiogenic programs, endothelial barrier function, and monocyte/macrophage behavior, processes frequently perturbed in chronic inflammatory disease states. Altered CD93 expression has been reported across immune- and vasculature-associated pathologies, making it a useful target for mechanistic studies of immune–stromal interactions.
CD93 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD93 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD93. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD93 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD93-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.